Karina A Zapata, James J McGinley, Chan-Hee Jo, Brandon A Ramo
{"title":"PROMIS指标与EOSQ-24在早发性脊柱侧凸中的并发有效性","authors":"Karina A Zapata, James J McGinley, Chan-Hee Jo, Brandon A Ramo","doi":"10.1007/s43390-025-01116-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the concurrent validity of 3 Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric metrics (Mobility, Pain Interference, and Anxiety) in Early Onset Scoliosis (EOS) by using the 24-item EOS Questionnaire (EOSQ-24) as an anchor.</p><p><strong>Methods: </strong>We retrospectively reviewed PRO data of children with EOS from April 2021 to June 2023. PROMIS Pain Interference, Mobility, Anxiety, and EOSQ-24 were simultaneously completed. Comparisons were made according to each EOSQ-24 domain with Pearson correlations. Correlations above 0.7 indicate a strong relationship, 0.4 to 0.69 indicate a moderate relationship, and 0.1 to 0.39 indicate a weak relationship.</p><p><strong>Results: </strong>236 children (84 boys, 152 girls) ages 10.4 ± 3.5 years (range: 5-19 years) with curves averaging 39° ± 22° were included. The strongest correlations between the 3 PROMIS metrics and each EOSQ-24 domain were between Mobility and EOSQ-24 Physical function (r = 0.75, p < 0.001), Pain Interference and EOSQ-24 Pain/discomfort (r = -0.68, p < 0.001), and Anxiety and EOSQ-24 Emotion (r = -0.51, p < 0.001). The weakest correlations between all 3 PROMIS metrics and each EOSQ-24 domain were for General health (r ≤ 0.35, p < 0.001), Financial impact (r ≤ 0.36, p < 0.001), and Pulmonary function (r ≤ 0.39, p < 0.001).</p><p><strong>Conclusion: </strong>The 3 PROMIS metrics (Mobility, Pain Interference, Anxiety) demonstrate moderate to strong validity with the related EOSQ-24 domains (Physical function, Pain/discomfort, Emotion). The weak associations between EOS-specific concerns demonstrate diverging constructs. This study supports the use of the EOSQ-24 given the adequate associations with the appropriate domains while highlighting the value of other EOSQ domains.</p>","PeriodicalId":21796,"journal":{"name":"Spine deformity","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Concurrent validity of PROMIS metrics with the EOSQ-24 in early onset scoliosis.\",\"authors\":\"Karina A Zapata, James J McGinley, Chan-Hee Jo, Brandon A Ramo\",\"doi\":\"10.1007/s43390-025-01116-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the concurrent validity of 3 Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric metrics (Mobility, Pain Interference, and Anxiety) in Early Onset Scoliosis (EOS) by using the 24-item EOS Questionnaire (EOSQ-24) as an anchor.</p><p><strong>Methods: </strong>We retrospectively reviewed PRO data of children with EOS from April 2021 to June 2023. PROMIS Pain Interference, Mobility, Anxiety, and EOSQ-24 were simultaneously completed. Comparisons were made according to each EOSQ-24 domain with Pearson correlations. Correlations above 0.7 indicate a strong relationship, 0.4 to 0.69 indicate a moderate relationship, and 0.1 to 0.39 indicate a weak relationship.</p><p><strong>Results: </strong>236 children (84 boys, 152 girls) ages 10.4 ± 3.5 years (range: 5-19 years) with curves averaging 39° ± 22° were included. The strongest correlations between the 3 PROMIS metrics and each EOSQ-24 domain were between Mobility and EOSQ-24 Physical function (r = 0.75, p < 0.001), Pain Interference and EOSQ-24 Pain/discomfort (r = -0.68, p < 0.001), and Anxiety and EOSQ-24 Emotion (r = -0.51, p < 0.001). The weakest correlations between all 3 PROMIS metrics and each EOSQ-24 domain were for General health (r ≤ 0.35, p < 0.001), Financial impact (r ≤ 0.36, p < 0.001), and Pulmonary function (r ≤ 0.39, p < 0.001).</p><p><strong>Conclusion: </strong>The 3 PROMIS metrics (Mobility, Pain Interference, Anxiety) demonstrate moderate to strong validity with the related EOSQ-24 domains (Physical function, Pain/discomfort, Emotion). The weak associations between EOS-specific concerns demonstrate diverging constructs. This study supports the use of the EOSQ-24 given the adequate associations with the appropriate domains while highlighting the value of other EOSQ domains.</p>\",\"PeriodicalId\":21796,\"journal\":{\"name\":\"Spine deformity\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Spine deformity\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s43390-025-01116-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Spine deformity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s43390-025-01116-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Concurrent validity of PROMIS metrics with the EOSQ-24 in early onset scoliosis.
Purpose: To evaluate the concurrent validity of 3 Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric metrics (Mobility, Pain Interference, and Anxiety) in Early Onset Scoliosis (EOS) by using the 24-item EOS Questionnaire (EOSQ-24) as an anchor.
Methods: We retrospectively reviewed PRO data of children with EOS from April 2021 to June 2023. PROMIS Pain Interference, Mobility, Anxiety, and EOSQ-24 were simultaneously completed. Comparisons were made according to each EOSQ-24 domain with Pearson correlations. Correlations above 0.7 indicate a strong relationship, 0.4 to 0.69 indicate a moderate relationship, and 0.1 to 0.39 indicate a weak relationship.
Results: 236 children (84 boys, 152 girls) ages 10.4 ± 3.5 years (range: 5-19 years) with curves averaging 39° ± 22° were included. The strongest correlations between the 3 PROMIS metrics and each EOSQ-24 domain were between Mobility and EOSQ-24 Physical function (r = 0.75, p < 0.001), Pain Interference and EOSQ-24 Pain/discomfort (r = -0.68, p < 0.001), and Anxiety and EOSQ-24 Emotion (r = -0.51, p < 0.001). The weakest correlations between all 3 PROMIS metrics and each EOSQ-24 domain were for General health (r ≤ 0.35, p < 0.001), Financial impact (r ≤ 0.36, p < 0.001), and Pulmonary function (r ≤ 0.39, p < 0.001).
Conclusion: The 3 PROMIS metrics (Mobility, Pain Interference, Anxiety) demonstrate moderate to strong validity with the related EOSQ-24 domains (Physical function, Pain/discomfort, Emotion). The weak associations between EOS-specific concerns demonstrate diverging constructs. This study supports the use of the EOSQ-24 given the adequate associations with the appropriate domains while highlighting the value of other EOSQ domains.
期刊介绍:
Spine Deformity the official journal of the?Scoliosis Research Society is a peer-refereed publication to disseminate knowledge on basic science and clinical research into the?etiology?biomechanics?treatment?methods and outcomes of all types of?spinal deformities. The international members of the Editorial Board provide a worldwide perspective for the journal's area of interest.The?journal?will enhance the mission of the Society which is to foster the optimal care of all patients with?spine?deformities worldwide. Articles published in?Spine Deformity?are Medline indexed in PubMed.? The journal publishes original articles in the form of clinical and basic research. Spine Deformity will only publish studies that have institutional review board (IRB) or similar ethics committee approval for human and animal studies and have strictly observed these guidelines. The minimum follow-up period for follow-up clinical studies is 24 months.